Butterworth Labs to expand operations by 15%
Part of a longer term plan to increase capacity.
Butterworth Laboratories has secured an additional facility in Hampton, Middlesex as part of a project to expand UK laboratory operations by 15% in 2017. This is the first phase of a longer term plan to deliver increased capacity of 60% by 2020.
The move is a result of consistently strong growth and will secure the company's Teddington facility as the UK laboratory operations, whilst providing the platform for continued growth in key areas. The expansion coincides with the appointment of David Hawkins, formerly the company's Chief Operating Officer, as Managing Director. Doris Butterworth continues on the board as Chairman along with the Finance Director John Gearey and newly appointed Non-Executive Director Patrick Stewart. The changes will provide continuity of leadership and position Butterworth to continue its success in the long term. David Hawkins said: "This underlines the commitment of Butterworth Laboratories to continuing to provide industry leading analytical support to our global customer base for the long-term and shows that independence and success can be maintained over a sustained period of time. Butterworth is showing that we have ambitions in-line with our global partners and continue to go from strength to strength."
Related News
-
News Pharmaceutical Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain.
-
News Merck KGaA to buy US biotech SpringWorks for US$3.9 billion
The German multinational pharmaceutical company Merck KGaA have signed a deal to buy US biotech company SpringWorks Therapeutics at an equity value of US$3.9 billion in a move to add rare cancer therapeutics to their pipelines.
-
News Cassava Sciences halts Alzheimer's drug trial after limited progress
Cassava Sciences have drawn a close to their investigations and development of the drug simufilam, which they intended to be used for the treatment of Alzheimer’s disease.
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines.
-
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries.
-
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement.